For research use only. Not for therapeutic Use.
Govorestat (AT-007) is an orally active brain-penetrant aldose reductase inhibitor with an IC50 value of 100 pM. Govorestat has the potential for galactose-1-phosphate uridyl transferase deficiency research[1].
Govorestat (AT-007) inhibits the conversion of glucose to Sorbitol. Govorestat significantly reduces Sorbitol levels in fibroblasts, induced pluripotent stem cell-derived (iPSC-derived) motor neurons, and Drosophila brains[1].
Govorestat (AT-007) feeding in Sord-deficient Drosophila mitigated synaptic degeneration and significantly improves synaptic transduction, locomotor activity, and mitochondrial function. Moreover, Govorestat treatment significantly reduces ROS accumulation in Drosophila CNS[1].
| Catalog Number | I017780 |
| CAS Number | 2170729-29-8 |
| Synonyms | 2-[4-oxo-3-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl]thieno[3,4-d]pyridazin-1-yl]acetic acid |
| Molecular Formula | C17H10F3N3O3S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H10F3N3O3S2/c18-17(19,20)8-1-2-13-12(3-8)21-14(28-13)5-23-16(26)10-7-27-6-9(10)11(22-23)4-15(24)25/h1-3,6-7H,4-5H2,(H,24,25) |
| InChIKey | ORQGHAJIWGGFJK-UHFFFAOYSA-N |
| SMILES | C1=CC2=C(C=C1C(F)(F)F)N=C(S2)CN3C(=O)C4=CSC=C4C(=N3)CC(=O)O |
| Reference | [1]. Yi Zhu, et al. Sorbitol reduction via govorestat ameliorates synaptic dysfunction and neurodegeneration in sorbitol dehydrogenase deficiency. JCI Insight. 2023 May 22;8(10):e164954. |
